Neoadjuvant Efficacy of Three Targeted Therapy Strategies for HER2-Positive Breast Cancer Based on the Same Chemotherapy Regimen

SIMPLE SUMMARY: Approximately 15–25% of breast cancers are human epidermal growth factor receptor 2 (HER2)-positive. With the progress in medicine, promising results have been shown by dual targeted therapy with new drugs in the neoadjuvant setting. In our study, we compared the effectiveness of thr...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Jiujun, Jiao, Dechuang, Wang, Chengzheng, Lu, Zhenduo, Chen, Xiuchun, Li, Lianfang, Sun, Xianfu, Qin, Li, Guo, Xuhui, Zhang, Chongjian, Qiao, Jianghua, Yan, Min, Cui, Shude, Liu, Zhenzhen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9497101/
https://www.ncbi.nlm.nih.gov/pubmed/36139667
http://dx.doi.org/10.3390/cancers14184508

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9497101/
https://www.ncbi.nlm.nih.gov/pubmed/36139667
http://dx.doi.org/10.3390/cancers14184508

Ejemplares similares